Theriva Biologics
TOVX
48 hedge funds and large institutions have $9.73M invested in Theriva Biologics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 5 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
0% more funds holding
Funds holding: 48 → 48 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
38% less capital invested
Capital invested by funds: $15.7M → $9.73M (-$6.01M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$110K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.4K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$22.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$19K |
| 5 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
+$15.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$145K |
| 2 |
VF
Virtu Financial
New York
|
-$125K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$122K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$55K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$22.8K |
TOVX Hedge Fund Activity: Q1 2018 in Review
48 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2018, worth a combined $9.73M — down 38% from $15.7M a quarter earlier.
Fund positioning in TOVX was balanced in Q1 2018: 5 funds opened new positions, 5 closed out, 9 added to existing stakes and 5 trimmed.
The largest buyer was William Blair & Company, adding an estimated $110K. The largest seller was Millennium Management, cutting an estimated $145K.
- 48 institutional investors held Theriva Biologics (TOVX) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $9.73M of Theriva Biologics stock for Q1 2018, down 38% quarter-over-quarter.
- 5 funds opened new Theriva Biologics positions in Q1 2018 and 5 closed out, a net change of 0 holders.
- The largest Theriva Biologics buyer in Q1 2018 was William Blair & Company, an estimated $110K added.
- The largest Theriva Biologics seller in Q1 2018 was Millennium Management, an estimated $145K sold.
Based on aggregated 13F filings for Q1 2018.